Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,423.61
(
1.26%
)
US TECH 100
22,659.60
(
1.47%
)
Dow Jones
45,629.98
(
0.92%
)
Brent Oil
107.41
(
-1.07%
)
Bitcoin
66,736.50
(
0.05%
)
News Focus
News Focus
Post# of 257318
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122827
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 189312

Sunday, 03/29/2015 12:58:07 PM

Sunday, March 29, 2015 12:58:07 PM

Post# of 257318
One improper criticism of CNAT is that their phase-2 biomarker trials are too short; in fact, one of the phase-2 trials in progress is following patients for 24 months (https://www.clinicaltrials.gov/ct2/show/NCT02138253 ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today